Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of $73.88 million. The enterprise value is $40.93 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q32 Bio has 14.63 million shares outstanding. The number of shares has increased by 27.51% in one year.
| Current Share Class | 14.63M |
| Shares Outstanding | 14.63M |
| Shares Change (YoY) | +27.51% |
| Shares Change (QoQ) | +2.88% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 14.75% |
| Float | 6.33M |
Valuation Ratios
The trailing PE ratio is 2.09.
| PE Ratio | 2.09 |
| Forward PE | n/a |
| PS Ratio | 1.37 |
| Forward PS | n/a |
| PB Ratio | 1.55 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1.37 |
| EV / Sales | 0.76 |
| EV / EBITDA | 2.37 |
| EV / EBIT | 2.42 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.37.
| Current Ratio | 4.85 |
| Quick Ratio | 4.31 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | n/a |
| Interest Coverage | 15.37 |
Financial Efficiency
Return on equity (ROE) is 125.06% and return on invested capital (ROIC) is 25.79%.
| Return on Equity (ROE) | 125.06% |
| Return on Assets (ROA) | 13.71% |
| Return on Invested Capital (ROIC) | 25.79% |
| Return on Capital Employed (ROCE) | 33.52% |
| Weighted Average Cost of Capital (WACC) | -0.14% |
| Revenue Per Employee | $2.24M |
| Profits Per Employee | $1.24M |
| Employee Count | 24 |
| Asset Turnover | 0.70 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +198.82% in the last 52 weeks. The beta is -1.02, so Q32 Bio's price volatility has been lower than the market average.
| Beta (5Y) | -1.02 |
| 52-Week Price Change | +198.82% |
| 50-Day Moving Average | 5.25 |
| 200-Day Moving Average | 3.20 |
| Relative Strength Index (RSI) | 41.99 |
| Average Volume (20 Days) | 356,938 |
Short Selling Information
The latest short interest is 350,520, so 2.40% of the outstanding shares have been sold short.
| Short Interest | 350,520 |
| Short Previous Month | 362,026 |
| Short % of Shares Out | 2.40% |
| Short % of Float | 5.54% |
| Short Ratio (days to cover) | 1.60 |
Income Statement
In the last 12 months, Q32 Bio had revenue of $53.74 million and earned $29.82 million in profits. Earnings per share was $2.42.
| Revenue | 53.74M |
| Gross Profit | 34.58M |
| Operating Income | 16.90M |
| Pretax Income | 29.82M |
| Net Income | 29.82M |
| EBITDA | 17.29M |
| EBIT | 16.90M |
| Earnings Per Share (EPS) | $2.42 |
Full Income StatementBalance Sheet
The company has $48.30 million in cash and $15.34 million in debt, with a net cash position of $32.95 million or $2.25 per share.
| Cash & Cash Equivalents | 48.30M |
| Total Debt | 15.34M |
| Net Cash | 32.95M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 42.01M |
| Book Value Per Share | 3.27 |
| Working Capital | 43.70M |
Full Balance SheetCash Flow
| Operating Cash Flow | -33.54M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 391,000 |
| Net Borrowing | -3.13M |
| Free Cash Flow | -33.54M |
| FCF Per Share | -$2.29 |
Full Cash Flow StatementMargins
Gross margin is 64.35%, with operating and profit margins of 31.45% and 55.49%.
| Gross Margin | 64.35% |
| Operating Margin | 31.45% |
| Pretax Margin | 55.49% |
| Profit Margin | 55.49% |
| EBITDA Margin | 32.18% |
| EBIT Margin | 31.45% |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.51% |
| Shareholder Yield | -27.51% |
| Earnings Yield | 40.36% |
| FCF Yield | -45.40% |
Analyst Forecast
The average price target for Q32 Bio is $13.00, which is 157.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 157.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q32 Bio has an Altman Z-Score of -1.18 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.18 |
| Piotroski F-Score | 3 |
